FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163521166> ?p ?o ?g. }

• W2163521166 endingPage "128" @default.
• W2163521166 startingPage "123" @default.
• W2163521166 abstract "The distribution of responses in study populations provides a novel method of comparing the benefit of two treatments. This 6‐week, randomised, placebo-controlled, double-blind study compared the effectiveness of oral montelukast with inhaled beclomethasone in chronic asthma by assessing the distribution and overlap of patient responses to therapy, as measured by a clinical outcome (asthma control days). A total of 730 adult patients with asthma, age 15–65 yrs, with a forced expiratory volume in one second (FEV₁) at baseline of 50–85% of predicted and ≥15% improvement in FEV₁ after inhaled β‐agonist were enrolled. After a 2–week placebo run-in period, patients were randomly allocated to receive montelukast (10 mg once daily), inhaled beclomethasone (200 µg twice daily) or placebo. The primary end-point (per cent of asthma control days) was compared between treatments as the overlap in the response distributions. The overlap of the distribution of responses between the montelukast and beclomethasone groups was 89% for per cent asthma control days and 96% for change from baseline in FEV₁. The mean (±sd) per cent asthma control days in the montelukast and beclomethasone groups was significantly higher than that in the placebo group (placebo 40.0±35.8, montelukast 50.7±37.1, beclomethasone 57.9±36.1). The mean differences between montelukast and placebo, beclomethasone and placebo, and montelukast and beclomethasone were significant. The mean per cent change (±sd) from baseline in FEV₁ was 12.1±18.7 and 13.9±20.8 in the montelukast and beclomethasone groups, respectively, and significantly greater than that in the placebo group (6.4±20.1); there was no significant difference between the montelukast and beclomethasone groups in mean values or response distribution. There was also no difference among treatment groups in the frequency of adverse experiences. A comparison of the response distribution is an important approach to comparing therapies; montelukast and beclomethasone provided similar response distributions for the end-point of per cent asthma control days over a 6‐week treatment period." @default.
• W2163521166 created "2016-06-24" @default.
• W2163521166 creator A5023716582 @default.
• W2163521166 creator A5024058644 @default.
• W2163521166 creator A5036429383 @default.
• W2163521166 creator A5036740466 @default.
• W2163521166 creator A5040633355 @default.
• W2163521166 creator A5067038065 @default.
• W2163521166 creator A5074264587 @default.
• W2163521166 creator A5081053735 @default.
• W2163521166 creator A5081715180 @default.
• W2163521166 creator A5085569895 @default.
• W2163521166 creator A5088362398 @default.
• W2163521166 date "2003-01-01" @default.
• W2163521166 modified "2023-09-26" @default.
• W2163521166 title "Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone" @default.
• W2163521166 cites W103650626 @default.
• W2163521166 cites W1501138121 @default.
• W2163521166 cites W1843291397 @default.
• W2163521166 cites W1909409123 @default.
• W2163521166 cites W1965926642 @default.
• W2163521166 cites W1968660451 @default.
• W2163521166 cites W1995471966 @default.
• W2163521166 cites W1996982788 @default.
• W2163521166 cites W2003374352 @default.
• W2163521166 cites W2004351423 @default.
• W2163521166 cites W2025604754 @default.
• W2163521166 cites W2034135161 @default.
• W2163521166 cites W2035942271 @default.
• W2163521166 cites W2042473166 @default.
• W2163521166 cites W2066950125 @default.
• W2163521166 cites W2073802634 @default.
• W2163521166 cites W2073817403 @default.
• W2163521166 cites W2081768819 @default.
• W2163521166 cites W2083113471 @default.
• W2163521166 cites W2108702725 @default.
• W2163521166 cites W2126810577 @default.
• W2163521166 cites W2127923724 @default.
• W2163521166 cites W2128558951 @default.
• W2163521166 cites W2198475357 @default.
• W2163521166 cites W2324627140 @default.
• W2163521166 cites W2585717783 @default.
• W2163521166 cites W2604596332 @default.
• W2163521166 cites W3024406083 @default.
• W2163521166 doi "https://doi.org/10.1183/09031936.03.00028803" @default.
• W2163521166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12570120" @default.
• W2163521166 hasPublicationYear "2003" @default.
• W2163521166 type Work @default.
• W2163521166 sameAs 2163521166 @default.
• W2163521166 citedByCount "55" @default.
• W2163521166 countsByYear W21635211662012 @default.
• W2163521166 countsByYear W21635211662013 @default.
• W2163521166 countsByYear W21635211662014 @default.
• W2163521166 countsByYear W21635211662015 @default.
• W2163521166 countsByYear W21635211662018 @default.
• W2163521166 countsByYear W21635211662019 @default.
• W2163521166 countsByYear W21635211662020 @default.
• W2163521166 crossrefType "journal-article" @default.
• W2163521166 hasAuthorship W2163521166A5023716582 @default.
• W2163521166 hasAuthorship W2163521166A5024058644 @default.
• W2163521166 hasAuthorship W2163521166A5036429383 @default.
• W2163521166 hasAuthorship W2163521166A5036740466 @default.
• W2163521166 hasAuthorship W2163521166A5040633355 @default.
• W2163521166 hasAuthorship W2163521166A5067038065 @default.
• W2163521166 hasAuthorship W2163521166A5074264587 @default.
• W2163521166 hasAuthorship W2163521166A5081053735 @default.
• W2163521166 hasAuthorship W2163521166A5081715180 @default.
• W2163521166 hasAuthorship W2163521166A5085569895 @default.
• W2163521166 hasAuthorship W2163521166A5088362398 @default.
• W2163521166 hasBestOaLocation W21635211661 @default.
• W2163521166 hasConcept C126322002 @default.
• W2163521166 hasConcept C142724271 @default.
• W2163521166 hasConcept C204787440 @default.
• W2163521166 hasConcept C27081682 @default.
• W2163521166 hasConcept C2776042228 @default.
• W2163521166 hasConcept C2776322731 @default.
• W2163521166 hasConcept C42219234 @default.
• W2163521166 hasConcept C71924100 @default.
• W2163521166 hasConceptScore W2163521166C126322002 @default.
• W2163521166 hasConceptScore W2163521166C142724271 @default.
• W2163521166 hasConceptScore W2163521166C204787440 @default.
• W2163521166 hasConceptScore W2163521166C27081682 @default.
• W2163521166 hasConceptScore W2163521166C2776042228 @default.
• W2163521166 hasConceptScore W2163521166C2776322731 @default.
• W2163521166 hasConceptScore W2163521166C42219234 @default.
• W2163521166 hasConceptScore W2163521166C71924100 @default.
• W2163521166 hasIssue "1" @default.
• W2163521166 hasLocation W21635211661 @default.
• W2163521166 hasLocation W21635211662 @default.
• W2163521166 hasOpenAccess W2163521166 @default.
• W2163521166 hasPrimaryLocation W21635211661 @default.
• W2163521166 hasRelatedWork W1998759167 @default.
• W2163521166 hasRelatedWork W2018270163 @default.
• W2163521166 hasRelatedWork W2033836503 @default.
• W2163521166 hasRelatedWork W2043240135 @default.
• W2163521166 hasRelatedWork W2069946977 @default.
• W2163521166 hasRelatedWork W2155991787 @default.
• W2163521166 hasRelatedWork W2163521166 @default.

• next